RAPH (Raphael Pharmaceutical) Total Equity: $-1.66 Mil (As of Mar. 2026)


RAPH Raphael Pharmaceutical Inc RAPH
37 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical Total Equity?

Raphael Pharmaceutical RAPH 37 Total Equity is $-1.66 Mil as of Mar. 2026. GuruFocus rates RAPH with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Raphael Pharmaceutical's total equity for the quarter that ended in Mar. 2026 was $-1.66 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Raphael Pharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for Raphael Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Total Equity Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 0.13 0.11 0.11 -0.74 -1.43

Raphael Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -1.05 -1.26 -1.43 -1.66
RAPH
37GF Score
Raphael Pharmaceutical Inc RAPH
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raphael Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Raphael Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=0.053-1.486
=-1.43

Raphael Pharmaceutical's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=0.003-1.665
=-1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-1.66 Mil mean?
Raphael Pharmaceutical (RAPH) has a Total Equity of $-1.66 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's Total Equity too high?
Raphael Pharmaceutical's current Total Equity is $-1.66 Mil. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Total Equity compare to TXMD and AYTU?
Raphael Pharmaceutical's Total Equity of $-1.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Raphael Pharmaceutical and its competitors. Raphael Pharmaceutical's current Total Equity is $-1.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Total Equity of $-1.66 Mil. The current Total Equity is $-1.66 Mil. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Total Equity is $-1.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score

Get the complete analysis for RAPH

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price